Tessa Therapeutics features in the The Business Times! Sharanya Pillai does a deep dive with Thomas Willemsen on our pipeline and future plans. Read the full story here: businesstimes.com.sg/garage/tessa-t… #TessaCell #CEO #cartcelltherapy #immunotherapy #innovation

Tessa Therapeutics's #allogeneic “off-the-shelf” CD30.CAR EBVST #celltherapy TT11X has been recognized in the “Most Promising Off-the-Shelf Therapies” category at the Asia-Pacific Cell & Gene Therapy Excellence Awards 2022 #ACGTEA2022 tessacell.com/2022/09/14/tes…

Thank you Asia-Pacific Cell & Gene Therapy Excellence Awards 2022 #ACGTEA2022 for recognizing Tessa under the “Most Promising Off-the-Shelf Therapies” category. We had a great time at the ceremony! #CARTtherapy #celltherapy #allogeneic #awardwinner #TessaCell

Tessa Therapeutics management team will be participating in the 2nd Annual Needham Biotech Private Company 1x1 Forum on October 18-19, 2022. Contact your Needham rep to book a meeting with Tessa. Read more at tessacell.com/2022/10/06/tes… #TessaCell #CARTCellTherapy #Needham

Tessa Therapeutics management team will be presenting at the Stifel Healthcare Conference 2022 on Nov 15, at Lotte New York Palace Hotel, New York City. Contact your Stifel rep to book a meeting with us. Read more at tessacell.com/2022/11/02/tes…

We are pleased to announce two upcoming orals and one poster presentation at #ASH2022. Presentations to focus on updated data from Tessa's allogenic and autologous programs targeting CD30 Positive Lymphomas. Read more here: tessacell.com/2022/11/03/tes… #ASH2022 #TessaCell

Tessa Therapeutics announces the execution of exclusive Global Commercial Rights Agreement with BCMHouston for 'Off-the Shelf' Epstein-Barr virus specific T-cell (EBVST) technology platform. Read more at: tessacell.com/2022/11/07/tes…

The Tessa Therapeutics team were delighted to present at Stifel 2022 Healthcare Conference. Thomas Willemsen, Ivan Horak, and Wilson Cheung are at the conference to take meetings and discuss the Tessa pipeline, growth plans and milestones #TessaCell #Biotechnology #CARtcelltherapy

Tune in to listen to our CEO Thomas Willemsen talk about the potential and path forward for our autologous and allogeneic programs in an interview with CGTLive® cgtlive.com/view/targeting…

#ASH22 is this weekend Dec 10-13! We are presenting two oral podium presentations and a poster on our #CARTcell therapies highlighting results from our ongoing #clinicaltrials. Presentation details: tessacell.com/2022/11/03/tes… #ASH22 #TessaASH22 #immunotherapy #CART #TessaCell

Our off-the-shelf #CARTcell therapy #TT11X showed a 79% overall response rate and complete responses in 43% of r/r CD30-positive lymphomas as presented at ASH22 #ASH22 #TessaASH22 #CancerTreatment #CART #Immunotherapy globenewswire.com/news-release/2…

#ASH22 #TessaASH22 #CancerTreatment #HodginLymphoma #SafetyData #Immunotherapy

New data from Tessa Therapeutics #CHARIOT study of autologous #CARTcell therapy #TT11 demonstrated a 73.3% overall response rate and 60% complete response rate; ctDNA identified as a potential efficacy biomarker: tessacell.com/2022/12/13/tes… MD Anderson Cancer Center #ASH22 #TessaASH22 #Cancer

#ASH22 #TessaASH22 #CancerTreatment #HodginLymphoma #Genetherapy #SafetyData #Immunotherapy #Phase2Data

Thanks ASH for hosting us again! Another incredible conference! We were honored to have multiple presentations featuring our #TT11X and #TT11 #CARTcell therapies at #ASH22. See our press releases at Tessacell.com

We are pleased to be recognized by Labiotech.eu as one of the top biotech companies to watch out for in 2023. Wishing everyone a great festive season ahead! labiotech.eu/in-depth/biote…

Tessa Therapeutics announces 2023 strategic outlook prioritizing its “off-the-shelf” CD30.CAR EBVST #allogeneic cell therapy platform and TT11X as its lead clinical program. Read more at: tessacell.com/2023/01/03/tes…

Tessa Therapeutics has appointed Steve Krognes as the company’s new Chairman of the Board of Directors. Krognes replaces Dr. Göran Ando as Chairman after nearly three years. Read more at: tessacell.com/2023/01/03/tes…

#CancerTreatment #allogeneic #celltherapy #Immunotherapy tessacell.com/2023/01/03/tes…

We are pleased to announce entry into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI) for testing our lead allogeneic CD30 CAR EBVST Therapy - TT11X in non-Hodgkin lymphomas. Read more here: tessacell.com/2023/03/08/tes…